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Summary We examined the ability of primary human tumour cells to secrete diffusible factors capable of
stimulating anchorage independent growth of normal rat kidney fibroblast (NRK) cells. Conditioned media
(CM) prepared from cells derived from 31/43 patients with adenocarcinoma of the breast, colon, ovary or
lung were found to induce growth of NRK cells in soft agar. The ability of the CM to induce anchorage
independent growth was enhanced in 25/35 cases by the presence of epidermal growth factor (EGF). The CM
did not compete with EGF for binding to the EGF receptor site. CM from cells derived from nonmalignant
effusions also supported the growth of NRK cells in soft agar. There was no significant difference in the
ability of the CM derived from malignant or normal cells to support NRK colony growth. The ability of
primary human tumour cells to clone in soft agar was compared to the ability of these cells to produce
diffusible colony stimulating factors for NRK cells. No correlation was observed between the ability of the
primary human tumour cells to clone in soft agar and their ability to induce anchorage independent growth
of NRK cells. The secretion of substances with TGF like activity may be a property of many types of
primary human cells.
Polypeptide growth factors that confer the
transformed phenotype on normal cells have been
termed transforming growth factors (TGFs) (Sporn
and Todaro, 1980). Recent studies have identified
at least two types of TGFs. Type a TGFs,
originally isolated from the CM of MSV
transformed cells, are single chain peptides
(MW6000) that show sequence homology to EGF.
The biological activity of these factors is not
potentiated by EGF. Type a TGFs compete with
EGF for binding to the EGF receptor (Todaro and
DeLarco, 1978). Type ,B TGFs have been found
intracellularly in both neoplastic and nonneoplastic
murine and human tissues (Roberts et al., 1982).
TGFs ,B are potentiated by EGF and these factors
do not compete with EGF for receptor binding.
TGFs of this type may play a role in normal cell
proliferation as well as neoplastic transformation.
The synergistic action of both types of TGF may
be required for full expression of the transformed
phenotype (Anzano et al., 1982).
The role of TGF in neoplastic progression in
humans is unclear (Nakamura et al., 1983). Todaro
et al. (1980) originally reported that human tumour
cell lines that clone well in soft agar released
greater quantities of TGFs than did normal cells or
tumour cells that grow poorly in agar. Nickell et al.
(1983) examined human benign and malignant
neoplastic and nonneoplastic tissue for the presence
of TGFs. They found that TGF-like activity was
not restricted to neoplastic tissues and that multiple
forms of TGF might be present in the same tissue.
Correspondence: A.W. Hamburger,
Received 26 June 1984; and in revised form, 26 September
1984.
In the present study, we examined the hypothesis
that those tumour cells that grow well in soft agar
are more efficient producers of transforming
peptides than those that grow poorly. Primary
human tumour cells were examined both for their
ability to clone in soft agar and to produce
diffusible factors that induce anchorage
independent growth of NRK cells. The results
indicate that most tumour cells tested produced
TGF like factors. However, the ability of primary
human tumour cells to clone in soft agar was not
related to their ability to produce NRK colony
stimulating factors.
Materials and methods
Preparation ofprimary human tumour cells
Tumour cells were obtained from surgical biopsies
of solid tumours from patients with adeno-
carcinoma of the ovary, colon, lung, or breast. The
neoplastic nature of the specimens was confirmed
by a clinical pathologist, and appropriate informed
consent was obtained in all cases. Tumour tissues
were dissociated into single cells under aseptic
conditions as described (Hamburger et al., 1982)
using collagenase, hyaluronidase and DNase. The
cells were washed and filtered through Nitex mesh
(22pm, Tekto, Elmsford, NY.) prior to plating in
agar. Differential counts were performed on slides
prepared with a cytocentrifuge and stained by the
Papanicolau and Wright-Giemsa methods. Viability
of cells (as determined by trypan blue exclusion)
ranged from 25 to 87% with a median of 75%.
Pleural or ascitic fluids (200-4000ml) were
obtained aseptically in heparinized (10Uml-1)
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vacuum bottles. Fluids were passed through sterile
gauze, centrifuged at 600g 10min, and cell
suspensions passed through 45 jm Nitex mesh.
Viability of cells derived from effusions ranged
from 47-98% with a median of 87%.
Tumour cells were used both to prepare
conditioned media (CM) and cloned in soft agar as
described below.
Culture assayfor tumour colonyforming cells
(TCFCs)
Cells were cultured as described by Hamburger &
Salmon (1977). One ml underlayers, containing
enriched McCoy's 5A medium in 0.5% agar, were
prepared in 35mm plastic petri dishes. Cells to be
tested were suspended in 0.3% agar in enriched
CMRL 1066 medium (Gibco Laboratories, Grand
Island, NY.) with 15% horse serum (Flow Labs,
Springfied, VA.) either in the absence or presence
of 50ngml -1 EGF (Collaborative Research,
Waltham, MA.). Each culture received 5 x 105 cells
in 1 ml agar-medium mixture and cultures were
incubated at 37°C in 5% CO2 humidified incubator.
Colonies were scored in an inverted phase
microscope 10-21 days after plating. Aggregates of
30 or more light refractile cells were considered
colonies.
Preparation ofconditioned media (CM)
Tumour cells (2 x 106 ml-1) were placed in 100 mm
tissue culture dishes in CMRL media containing
2% horse serum, insulin (5 jgml-1), transferrin
(5 jgml-1) selenium (5 ngml-1) (Collaborative
Research) and soy bean lipids (20 jgml-1)
(Boehringer-Manheim, Indianapolis, IN.). Media
was collected 24h after initiation of the cultures,
centrifuged at 600g 20min, and filtered through
0.45 and 0.22 jm filters (Millipore, Bedford, MA.).
NRK colony assay
NRK cells, clone 49F (ATCC CRL 1570) were
grown in Dulbecco's modified Eagle's medium
(GIBCO) containing 10% calf serum (Sterile
Systems, Logan UT.). The cells were subcultured
twice weekly and used for assay only when
subconfluent. Base layers of 1 ml of 0.5% agar
(Difco, Detroit, MI.) containing enriched CMRL,
with 2% horse serum, were prepared in 35 mm Petri
dishes. EGF (50 ngml -1) was added to these
underlayers as indicated. CM, derived from human
tumour cells as described, was substituted for the
control CMRL media as stated. A ml overlayer
containing 2 x 104 NRK cells in DMEM and 10%
calf serum was applied. Plates were incubated at
37°C in a humidified atmosphere of 5% CO2 in air
and colonies of >40 cells were counted between 7-
10 days after plating in a Zeiss inverted phase
microscope. In all assays, a positive control
containing a known level of TGF like activity and
a negative control containing enriched CMRL
media with 2% serum were included. Half the
plates in each control group contained EGF. No
colonies were observed in the presence of media
controls. Between 5-40 colonies were observed in
the presence of EGF alone. Results are reported
after subtracting the number of colonies observed
in the presence of EGF alone where appropriate.
Statistical analysis
The Student's t test was used on paired samples to
compare control to experimental groups. Four or
five plates were scored per point. Spearmann rank
correlation coefficient, the Wilcoxon signed rank
test (for paired samples) or two sample test (for
independent samples) were used where appropriate
as indicated in the text. Statistical significance was
determined at the 5% level.
Results
Production ofNRK colony stimulatingfactors by
human tumour cells
Primary human tumour cells, derived from either
12 solid tumours (8 ovarian, 2 colon, 2 lung) or 40
malignant effusions (24 ovarian, 7 breast, 4 colon, 5
lung) were screened for their ability to secrete
diffusible factors capable of stimulating growth of
NRK cells in soft agar. Table I shows the results of
experiments in which CM, prepared as described,
were used to stimulate anchorage independent
growth of NRK cells. Thirty-one of 43 specimens
tested secreted factors that stimulated the growth of
NRK cells (Table I). There were no significant
differences in the ability of tumour cells derived
from different sites to secrete NRK colony-
stimulating factors (NRK-CSFs) (Wilcoxon two
sample test ofa 5% probability). CM induced colony
growth in only 13/35 cases in the absence of EGF.
The number of colonies stimulated by CM in the
absence of EGF was low (median 120 range 0-632)
(Table I). As EGF enhances type I? NRK
stimulatory activity, we examined the effect of EGF
on the activity of the CM. In 25/35 cases, the effect
of CM was potentiated by EGF at 50ngml-'. The
addition of EGF gave a 5-20 fold enhancement
(median 9.5) of activity. In 2 cases, the colony
stimulating activity of the CM was decreased by
addition of EGF and in 8 cases there were no
significant changes.
The ability of CM to compete with EGF for
receptor binding was examined in 43 cases by the
method of Roberts et al. (1981). No EGF receptorTRANSFORMING GROWTH FACTOR SECRETION
Table I Stimulation of NRK colony formation by conditioned media from human tumour cells
-EGF +EGF
No. ofcolonies/2 x 104 No. ofcolonies/2 x 104
Tumour site No. activea Median (Range) No. active Median (Range)
Ovary 8/22 76 (0-632) 15/22 422 (0-1032)
Colon 2/6 0 (0.249) 3/6 40 (0-2400)
Breast 3/4 20 (0-206) 5/5 190 (25-490)
Lung 0/3 3 0 5/5 120 (40-225)
aNumber of samples ofCM that stimulated NRK colony formation.
competing activity was observed at dilutions of CM
which were able to induce soft agar colony
formation (data not shown).
The ability of TGF to enhance growth of NRK
cells was initially postulated to be associated with
the transformed state (Todaro et al. 1980).
Therefore, we compared the ability of CM derived
from malignant and non-malignant cells to
stimulate soft agar growth of NRK cells (Figure 1).
CM derived from 9/11 non-malignant samples
(congestive heart failure, kidney failure) contained
NRK-CSF activity. Seven of 10 samples of CM
were active in the absence of EGF and 9/11 were
active in the presence of EGF. There was no
significant difference in the ability of non-malignant
or malignant cells to produce NRK CSFs
(Wilcoxon 2 sample test at 5%).
Ability ofeffusionfluids to support NRK colony
growth
We examined the ability of effusion fluids, derived
from 30 patients w4h adenocarcinoma of the breast,
colon, ovary or lung to support NRK colony
formation. Overall, fluids were able to support
colony growth in 28/30 cases (Table II). In 16/30
cases, CM stimulated colony formation in the
absence of EGF. In 28/30 cases, growth was
apparent in the presence of EGF. The ability of the
fluids to stimulate NRK colony formation was
enhanced by EGF in 24/30 cases. The degree of
enhancement ranged from 1.2 to 6.7 times control
values (median 5.3). The ability of CM derived from
cells of individual patients was compared to the
ability of autologous effusion fluid to support
growth. In all cases, fluid induced more colonies
than CM produced in vitro by autologous cells.
However, there was no correlation between the
ability of CM and autologous fluid to support
growth (Spearman rank correlation, 5% probability)
(data not shown).
The ability of effusion fluids derived from patients
with non-malignant disease to support colony
growth was examined (Table II). In 9/14 cases, non-
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Figure 1 Ability of CM from cells derived from human malignant and nonmalignant effusions to induce
growth of NRK colonies in soft agar. (a) number of colonies formed in the absence of EGF. (b) number of
colonies formed in the presence of EGF.
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Table II Stimulation of NRK colony growth by effusion fluid
-EGF +EGF
No. ofcolonies/2 x 104 No. ofcolonies/2 x 104
Tumour site No. activea Median (Range) No. active Median (Range)
Ovary 8/14 40 (0-1021) 14/14 400 (168-2580)
Breast 5/6 44 (30-1985) 6/6 720 (344-1424)
Colon 0/4 0 2/4 35 (0-516)
Lung 5/6 88 (0-2024) 6/6 608 (280-1448)
Non-malignant 9/14 91 (0-1323) 14/14 450 (40-1680)
aNumber of samples of fluid that stimulated NRK colony formation.
malignant effusion fluid stimulated NRK colony
formation in the absence of EGF. Growth in the
presence of EGF was observed in all 14 cases. The
number of colonies stimulated by non-malignant
fluid was not significantly different than the number
of colonies stimulated by malignant fluids
(Wilcoxon two sample test, 5% probability)
(Table II).
Comparison ofthe ability ofprimary human tumour
cells to clone in soft agar and the ability to secrete
NRK CSFs
The ability of malignant cells to clone in soft agar
was initially postulated to be related to the ability
to produce extra-cellular TGFs. Thus, tumour cell
lines that formed colonies in soft agar at low cell
densities produced more TGFs than tumour cell
lines that cloned poorly (Todaro et al., 1980). We,
therefore, compared the ability of primary human
tumour cells to clone in soft agar to their ability to
secrete extra-cellular CSFs for NRK cells. The
results are shown in Figure 2. Specimens from 27
patients with adenocarcinoma of the breast, colon,
ovary or lung were examined. The ability of cells to
clone in soft agar varied from patient to patient.
The number of colonies for the different tumour
types were as follows (median and range): ovary,
n=14,332 (0-2000); colon, n=7,25 (0-112); lung,
n=2,290 (6-520); breast, n=3,183 (0-256). There
was no correlation between the ability of human
tumour cells to clone in soft agar at a
concentration of 5 x 105 cellsml-1 and their ability
to produce TGFs (Figure 2).
Discussion
This study demonstrates the common occurrence in
human neoplastic and nonneoplastic tissue of
substances that stimulate anchorage independent
growth of NRK cells. The biological activity of
these diffusible substances was similar to that of
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Figure 2 Relationship between the ability of primary
human tumour cells to clone in soft agar and the
ability to produce factors that stimulate NRK growth
in soft agar.
TGFs previously described (Sporn & Todaro,
1980). The presence of CSFs in the media may have
been due to production of these factors by tumour
cells in vitro or release of intracellular substances by
dying cells.
In the majority of cases tested, the colony
stimulating ability of these substances found in
conditioned media was potentiated by the addition
EGF. Thus, the activity of these factors most
clearly resembles the TGFs described by Roberts et
al. (1981). Whether the EGF induced potentiation
was due to enhancement of the activity of different
substances already active in the absence of EGF, or
to the activity of factors dependent on EGF is not
known. However, Nickell et al. (1983) have
demonstrated that the addition of EGF to extracts
of primary human tumours increased the activity of
19r
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TGF active in the absence of EGF. EGF did not
elicit functional activity of additional factors.
We were unable to find significant differences in
the ability of nonneoplastic and neoplastic cells to
secrete CSF active either in the absence or presence
of EGF. In addition, TGF like activity was found
in both nonneoplastic and malignant effusion
fluids. This finding is consistent with previous
reports indicating TGF activity in nonneoplastic
human (Halper & Moses, 1983) and murine
(Twardzik, et al., 1982) tissues and in human
platelets (Assosian, 1983) and sera (Childs et al.,
1982). It is therefore unlikely that simply assaying
CM or sera for the presence of TGF-like activity
can be used as a screen for malignant potential.
Our work also indicated that the ability of
primary human tumour cells to clone in soft agar
was unrelated to the ability of these cells to
produce substances with NRK colony-stimulating
activity. Initial reports (Todaro et al., 1980) had
suggested that the ability of human tumour cell
lines to clone in agar was related to their ability to
produce TGF-like compounds. Similarly, a
correlation was found between the ability of SV-40
transformed rat embryo cells to form colonies in
agar and their production of TGF-like substances
(Kaplan et al., 1981).
Several factors may have accounted for the lack
of correlation between the ability of human cells to
clone in soft agar and the production of CSFs for
NRK cells. First, only crude CM was used in these
studies. Inhibitors of anchorage independent
growth (Brattain & Levine, 1984) found in acid
ethanol extracts of human tumour cell lines, may
have been variably present in the CM. Second
colony stimulating factors released by tumour cells
may be tissue or species specific. A family of TGF-
like compounds of differing MW and biological
activity has been found in acid ethanol extracts of
human tumour cells (Nickell et al., 1983). Four
classes of compounds have been identified which
are specific for either NRK, AKR-B, or human
SW-13 adenocarcinoma cells. The factor, or factors,
that are most relevant to the clonogenic growth of
primary huihan tumour cells are not known. Thus,
the NRK assay may not be appropriate for
determining biological activity of factors produced
by human tumour cells. Third, human tumour cells
may produce factors that induce anchorage
independent growth when plated at high, but not
clonal densities. Thus, factors for NRK anchorage
indepencence may have been produced only when
human tumour cells were plated at high densities in
monolayer culture. McClure (1983) found that SV-
40 transformed 3T3 fibroblasts could clone in
serum-free media only with the addition of CM
derived from monolayer high density cultures of
3T3 fibroblasts.
In addition, serum contains factors that
contribute to the anchorage independent phenotype
(Kaplan et al., 1982). All primary human tumour
clonal assays contain 15% horse sera. Thus, high
levels of TGF like activity in sera may have
overwhelmed any cellular contribution of TGF like
factors. This is borne out by the fact that a linear
increase in the number of tumour colonies with
increasing numbers of cells plated has been
reported (Hamburger & Salmon, 1977) and was
consistently seen in this study (data not shown).
Such a linear increase would not be expected if the
major source of TGF-like compounds was cellularly
derived. Attempts to clone primary human tumour
cells in serum-free media to more directly test the
role of cellular derived TGFs have been
unsuccessful (Hamburger et al., 1983).
Finally, it is possible that TGF-like compounds
produced by human tumour cells may not be
involved in neoplastic transformation, but have
other important growth-promoting activities.
In summary, we have found production of
diffusible substances that stimulate anchorage
independent growth of NRK cells by a variety of
neoplastic and benign primary human cells. The
ability of these cells to clone in agar was unrelated
to their ability to produce factors that induce
anchorage independent growth of NRK cells in
vitro. It is likely that these colony stimulating
factors play an important role in normal growth
and development. Changes in the production and
response to such factors could play a role in
neoplastic transformation.
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